Endo, Inc., a generic and specialty branded pharmaceutical company, announced that it was selling its international pharmaceutical businesses to Knight Therapeutics Inc. The businesses are primarily operated through Canada-based specialty pharmaceutical company Paladin Pharma Inc.
Total cash consideration for the sale is up to approximately $105 million, consisting of approximately $79 million paid at closing, approximately $11 million related to certain permitted holdbacks and up to $15 million in future payments contingent upon the achievement of certain milestones.
Knight Therapeutics Inc. is a specialty pharmaceutical company. In 2024, according to the company’s latest financial reports, the company generated $365 million in revenue. It is based in Montreal, Canada.
According to data captured in the LevinPro HC database, this transaction marks the 24th Pharmaceuticals acquisition of 2025. There were 66 Pharmaceutical transactions announced throughout all of 2024. This is Knight Therapeutics’ first acquisition of 2025.
